SciBase Receives US Patent Approval for Its Electrodes with Micro-Needles
May 25 2015 - 1:41AM
Business Wire
SciBase, a Swedish medtech company that develops and markets a
new method for early detection of malignant melanoma, has received
approval from the United States Patent and Trademark Office (USPTO)
regarding its patent application for its electrodes with
micro-needles. The method is already approved in 12 European
countries, Australia and Canada. All patents are valid through
2023.
SciBase’s solution Nevisense is based on a technology called
Electrical Impedance Spectroscopy (EIS), which uses the varying
electrical properties of human tissue to categorize cellular
structures and thereby detect malignancies. Malignant melanoma is a
fast growing kind of skin cancer, which appears in the epidermis
right under the cornified layer. Nevisense’s electrodes are
equipped with microscopic needles that measure the electric
impedance in the cells below, where malignant melanoma appears. The
technique is essential for detecting the early stages of skin
cancer.
”Right now, Nevisense is in the approval process for sales and
marketing in the United States, which is a future key market for
us. The approval of our patent is thus an important step in our
global expansion. Electrodes with micro-needles can potentially be
used to detect other types of cancer as well,” says Simon Grant,
CEO of SciBase.
SciBase holds a total of 49 registered patents and currently
have another 12 active patent applications pending in six patent
families.
Skin cancer is the most common cancer in the world, accounting
for nearly half of all cancers. It has been estimated that nearly
half of all Americans who live to age 65 will develop skin cancer
at least once. Malignant melanoma is the most fatal form of skin
cancer causing the majority (75 percent) of deaths related to skin
cancer, although it only accounts for 4 percent of all skin cancer
cases. Worldwide, doctors diagnose about 230,000 new cases of
melanoma yearly. The key to management is early detection.
About SciBase and Nevisense
SciBase AB is a Swedish medical technology company,
headquartered in Stockholm that has developed a unique
point-of-care device for the accurate detection of malignant
melanoma. Its product, Nevisense, helps doctors to detect malignant
melanoma, the most dangerous type of skin cancer. SciBase was
founded by Stig Ollmar, Associate Professor at The Karolinska
Institute in Stockholm, Sweden. Nevisense is based on substantial
research and has achieved excellent results in the largest clinical
study ever conducted on the detection of malignant melanoma.
Nevisense is CE marked in Europe, has TGA approval in Australia,
and is awaiting FDA clearance in the United States. Nevisense is
based on a technology called Electrical Impedance Spectroscopy
(EIS), which uses the varying electrical properties of human tissue
to categorize cellular structures and thereby detect malignancies.
Further is available on www.scibase.com.
This information was brought to you by Cision
http://news.cision.com
View source
version on businesswire.com: http://www.businesswire.com/news/home/20150524005053/en/
SciBase ABSimon Grant, CEOPhone: +46 72 887 43 99Email:
simon.grant@scibase.com